Consider this illustrative scenario: a patient at 24 weeks’ gestation is asymptomatic and has a maternal carboxyhemoglobin (COHb) of 12% after a suspected household exposure. If the exposure is credible, this is not automatically a low-risk clearance problem. The key question is not whether 12% crosses a universal hyperbaric-oxygen threshold. It is whether a maternal blood level can stand in for fetal exposure. It cannot.
If the household exposure is credible, start oxygen and assess the mother while arranging obstetric and toxicology input. First clarify the exposure duration and timing, whether she received oxygen before the blood sample, and whether she smokes combustible tobacco. These details help interpret the maternal result; they do not provide a direct measurement of fetal CO burden.
Why the maternal number can understate fetal risk
CO crosses the placenta. Fetal blood may reach a higher COHb concentration than maternal blood, and fetal CO elimination can be substantially slower. Fetal hemoglobin binds CO avidly, while CO trapped in fetal blood must ultimately clear through the maternal circulation and lungs.
The fetal elimination half-life has been estimated at up to four to five times the maternal half-life. Treat that as a useful explanation for the lag—not as a precise bedside calculator. There is no routine way to measure fetal COHb in utero, and the mother’s measured value cannot tell you the fetus’s peak level or how much CO remains.
The maternal COHb is also time-sensitive. It can fall after the patient leaves the exposure or receives oxygen, so a level drawn later may not reflect the peak exposure. Maternal symptoms and COHb are important data, but neither alone establishes fetal wellbeing.
| Finding | What it helps assess | What it cannot establish alone |
|---|---|---|
| Maternal COHb | Recent maternal CO exposure, interpreted with smoking, timing, and oxygen already received | Fetal COHb or fetal injury |
| Maternal symptoms and examination | The mother’s current clinical state and need for escalation | Whether the fetus has been exposed or is unaffected |
| Fetal heart assessment | Fetal status at the time of assessment | Fetal CO burden or assurance against later effects |
A conventional pulse oximeter is not a substitute for blood CO-oximetry when CO exposure is suspected. A reassuring maternal appearance—or a reassuring fetal assessment at one moment—does not erase the exposure history or the slower fetal washout.
What changes in the emergency department
The first treatment remains prompt high-concentration oxygen, usually delivered with a nonrebreather mask, while the patient is removed from the exposure. Do not wait for fetal monitoring or a hyperbaric decision before treating the mother: improving maternal oxygen availability is central to supporting both patients.
At the same time, obtain an obstetric consultation and arrange gestation-appropriate fetal assessment. At 24 weeks, the appropriate monitoring plan depends on local viability practice and the obstetric team’s judgment. Fetal monitoring can identify concerning physiology and help guide the next steps; it cannot measure fetal COHb or independently rule out fetal exposure.
Assess the mother for neurologic, cardiac, and metabolic effects as indicated by the exposure and presentation. Reassess her clinical status and COHb in context, rather than treating a single number as a severity score or a discharge test. A maternal COHb of 12% alone is not an indication for delivery. Delivery decisions should be based on the obstetric situation and the balance of maternal and fetal risks; delivery does not replace treatment of CO poisoning.
Hyperbaric oxygen: consult early, avoid a false cutoff
Current CDC guidance describes hyperbaric oxygen as the treatment of choice for pregnant patients, even when maternal poisoning appears less severe. Pregnancy-specific comparative evidence is limited, and guidance differs in how prescriptive it is. The ACEP adult emergency-department policy approved in 2025 explicitly excludes pregnant patients and fetal exposures, so its adult recommendation cannot settle this case.
For an asymptomatic pregnant patient with a reported COHb of 12%, the useful action is an early discussion with a hyperbaric service, poison control or medical toxicology, and obstetrics—not automatic reassurance and not a rigid rule based on one percentage. Consider the credibility and timing of exposure, oxygen already given, maternal course, fetal findings, chamber access, and the risks of transport. A fetal abnormality or maternal deterioration increases urgency, but should not be treated as the only reason to seek expert input.
Oxygen duration also needs careful wording. Because fetal clearance lags, maternal COHb normalization does not prove that fetal CO has cleared. UKTIS pragmatically recommends high-concentration oxygen for five times the nonpregnant interval needed to reduce maternal COHb to normal. This is not an evidence-based universal duration. Use serial assessment and specialist recommendations rather than converting that estimate into a mandatory formula—or stopping solely because the maternal number has normalized.
Practical takeaways
- In pregnancy, maternal COHb is not a fetal dose. A level of 12% and an asymptomatic mother do not by themselves establish fetal safety.
- Give high-concentration oxygen promptly and assess the mother while arranging obstetric and toxicology input.
- At 24 weeks, use gestation-appropriate fetal assessment; a reassuring tracing is a snapshot, not a fetal COHb measurement.
- Seek early hyperbaric consultation. Pregnancy-specific evidence and recommendations differ, so neither a universal COHb cutoff nor a general adult policy resolves the decision.
- Do not treat the fivefold oxygen-duration estimate as a validated rule, and do not use maternal COHb normalization alone as proof of fetal clearance.
